Cxbladder is a clinically proven cutting-edge genomic urine test that quickly and accurately detects or rules out bladder cancer in patients presenting with blood in the urine (or hematuria) and those being monitored for recurrence. The test works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer.

Cxbladder is discreet, quick, non-invasive and painless, typically giving you meaningful results within five working days. It comes as a suite of test options, each optimized for a different point in the patient journey.

Triage: Incorporates known bladder cancer risk factors to help rapidly rule out the disease.
Detect: Designed to work alongside other tests to improve overall detection accuracy.
Monitor: Optimised for bladder cancer surveillance, reducing the need for further invasive tests

Cxbladder gives you peace of mind and will help your doctor make informed treatment decisions.

Learn more at: https://www.cxbladder.com

Highlighting key topics in cancer surveillance, this video from the National Cancer Institute (NCI) looks at bladder cancer trends in the United States.

Here is NCI's information on bladder cancer: www.cancer.gov/bladder
Find more cancer statistics from NCI's Surveillance, Epidemiology, and End Results (SEER) Program: http://www.seer.cancer.gov

Bladder cancer is a common type of cancer that begins in the cells of the bladder, a hollow muscular organ in the lower abdomen that stores urine. Bladder cancer signs and symptoms can include blood in the urine, frequent or painful urination, and back pain.

"The vast majority of bladder cancer patients are diagnosed with cancer that's not imminently life-threatening, but they tend to be aggressive," says Dr. Mark Tyson II, a Mayo Clinic urologic surgeon. "So bladder cancers, even if they're not life-threatening when they're first diagnosed, tend to recur."

For this reason, people with bladder cancer typically need follow-up tests for years after treatment to look for the recurrence of their cancer.

May is Bladder Cancer Awareness Month. On this Mayo Clinic Q&A podcast, Dr. Tyson discusses bladder cancer diagnosis, staging and treatment.

____________________________________________

For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.

FOR THE PUBLIC: More health and medical news on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/​

FOR THE MEDIA ONLY: Register at https://newsnetwork.mayoclinic.org/re...​ to access clean and nat sound versions of this video on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/

Mayo Clinic https://mayocl.in/3tNMAdF
Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/
Like Mayo Clinic on Facebook: https://www.facebook.com/
Follow Mayo Clinic on Twitter: https://twitter.com/MayoClinic

An examination of strategies for the treatment of advanced urothelial cancer after progression of disease following maintenance immunotherapy with avelumab.

Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive

"Dr. Inderbir Gill, Founding Executive Director of the USC Institute of Urology, answers questions about bladder cancer.

For more information, visit:
http://urology.keckmedicine.org
or call (323) 442-4827.

Music:
""Mining by Moonlight"" Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0
http://creativecommons.org/licenses/by/3.0/"

Link to Full Transcript: https://bit.ly/36D8xFD

Dr. Shilpa Gupta of the Cleveland Clinic reviews the most common side effects of bladder cancer therapies.

Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Learn more about Dr. Gupta: https://my.clevelandclinic.org..../staff/24785-shilpa-

Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: powerfulpatients.org/connect

How Does Immunotherapy Work? A video with animation showing how bladder cancer immune therapies work was produced by https://bcan.org, the Bladder Cancer Advocacy Network (BCAN).

Read the transcript by clicking here: http://bit.ly/2HEqkde

In this video about immunotherapy for bladder cancer treatment, Peter H. O’Donnell, MD, meets with Kevin, a bladder cancer patient, and his wife. They discuss Kevin's treatments to date, the results of his scans, and his immune therapy options as the next best treatment for his bladder cancer.

The patient’s scans show that rounds of chemotherapy did not eliminate the bladder cancer and it is growing again. Since the chemotherapy did not kill the cancer, Dr. O’Donnell offers immunotherapy, a relatively new cancer treatment, as his recommended next step. This newer IV-administered treatment is different than Bacillus Calmette-Guerin (BCG) therapy, an older bladder cancer treatment which is administered directly to the bladder.

Dr. O’Donnell explains how immunotherapy works by drawing on a paper. Animations then show bladder cancer cells, immune cells, and how they interact. A protein on the surface of bladder tumor cells allows it to hide from the body’s immune cells. As a result, the body’s blinded immune cells can’t fight and destroy the bladder cancer tumor, so it grows.

When successful, immune therapy drugs remove the surface protein signals from the cancer cells, allowing the body’s own immune cells to recognize and fight the cancer cells and shrink the bladder tumor. In addition, the immune therapy stimulates and revs up the immune cells.

Side effects of immunotherapy differ from those of chemotherapy for bladder cancer. Most people receiving immunotherapy have minimal side effects, such as rashes and tiredness. In rare instances though, the immune system gets too revved up, resulting in immune cells attacking the body’s other healthy cells in an auto-immune response. If this response occurs, the auto-immune attacks can usually be reversed with steroids.

Of the two main bladder cancer treatment options, chemotherapy, even with its bladder cancer treatment side effects, is the usual first “tried and true treatment” for a patient with a bladder cancer diagnosis.

But in patients who can’t tolerate chemotherapy or for whom chemotherapy stops working, immunotherapy can be the second step standard of care for bladder tumor treatment. It has been shown to shrink tumors in 20 percent of patients, and it freezes the tumor size in another 20 percent. So almost half of patients benefit from immunotherapy. And for the patients who do benefit, the bladder tumor may not grow again for many years.

Immunotherapy is administered by IV infusion, usually in an outpatient medical center.

When chemotherapy hasn’t worked, immunotherapy can give hope to bladder cancer patients and improve bladder cancer survival.

About BCAN:
The Bladder Cancer Advocacy Network (BCAN) is a community of patients, caregivers, survivors, advocates, medical and research professionals united in support of people touched by bladder cancer.

Since our founding in 2005, BCAN has been on the front-lines advocating for greater public awareness and increased funding for research to identify effective treatments and eventually, a cure for bladder cancer. For more information, visit: https://www.bcan.org/.